Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2018

Open Access 01-12-2018 | Review

Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases

Authors: Helena Crisford, Elizabeth Sapey, Robert A. Stockley

Published in: Respiratory Research | Issue 1/2018

Login to get access

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a common, multifactorial lung disease which results in significant impairment of patients’ health and a large impact on society and health care burden. It is believed to be the result of prolonged, destructive neutrophilic inflammation which results in progressive damage to lung structures. During this process, large quantities of neutrophil serine proteinases (NSPs) are released which initiate the damage and contribute towards driving a persistent inflammatory state.
Neutrophil elastase has long been considered the key NSP involved in the pathophysiology of COPD. However, in recent years, a significant role for Proteinase 3 (PR3) in disease development has emerged, both in COPD and other chronic inflammatory conditions. Therefore, there is a need to investigate the importance of PR3 in disease development and hence its potential as a therapeutic target. Research into PR3 has largely been confined to its role as an autoantigen, but PR3 is involved in triggering inflammatory pathways, disrupting cellular signalling, degrading key structural proteins, and pathogen response.
This review summarises what is presently known about PR3, explores its involvement particularly in the development of COPD, and indicates areas requiring further investigation.
Literature
1.
GOLD: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2017.
2.
Baici A, Szedlacsek SE, Fruh H, Michel BA. pH-dependent hysteretic behavior of human Myeloblastin (leucocyte proteinase 3). Biochem J. 1996;317:901–5.PubMedPubMedCentralCrossRef
3.
Karatepe K, Luo HR. Proteinase 3 is expressed in stem cells and regulates bone marrow hematopoiesis. Blood. 2015;126:1159.CrossRef
4.
Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and Cathepsin G: physiochemical properties, activity and Physiopathologcal functions. Biochemie. 2008;90:227–42.CrossRef
5.
Zimmer M, Medcalf RL, Fink TM, Mattmann C, Lichter P, Jenne DE. Three human elastase-like genes Coordingately expressed in the Myelomonocyte lineage are organised as a single genetic locus on 19pter. Proc Natl Acad Sci U S A. 1992;89:5.CrossRef
6.
Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane In vitro and In vivo. Clin Exp Immunol. 1994;95:244–50.PubMedPubMedCentralCrossRef
7.
Witko-Sarsat V, Cramer EM, Hieblot C, Guichard J, Nusbaum P, Lopez S, Lesavre P, Halbwachs-Mecarelli L. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly Mobilizable intracellular Pool distinct from Azurophil granules. Blood. 1999;94:2487–96.PubMed
8.
Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V. Bimodal Distrubution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the Polymorphonuclear neutrophil Pool. FEBS Lett. 1995;374:29–33.PubMedCrossRef
9.
Csernok E, Ludemann J, Gross WL, Bainton DF. Ultrastructural localisation of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol. 1990;137:1113–20.PubMedPubMedCentral
10.
Korkmaz B, Jaillet J, Jourdan M-L, Gauthier A, Gauthier F, Attucci S. Catalytic activity and inhibition of Wegener antigen proteinase 3 on the cell surface of human Polymorphonuclear neutrophils. J Biol Chem. 2009;284:19896–902.PubMedPubMedCentralCrossRef
11.
Korkmaz B, Lesner A, Letast S, Mahdi YK, Jourdan ML, Dallet-Choisy S, Marchand-Adam S, Kellenberger C, Viaud-Massuard MC, Jenne DE, Gauthier F. Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis). Semin Immunopathol. 2013;35:411–21.PubMedCrossRef
12.
Hajjar E, Broemstrup T, Kantari C, Witko-Sarsat V, Reuter N. Structures of human proteinase 3 and neutrophil elastase - so similar yet so different. FEBS J. 2010;277:2238–54.PubMedCrossRef
13.
Hajjar E, Korkmaz B, Gauthier F, Brandsdal BO, Witko-Sarsat V, Reuter N. Inspection of the binding sites of proteinase 3 for the Design of a Highly Specific Substrate. J Med Chem. 2006;49:1248–60.PubMedCrossRef
14.
Guarino C, Gruba N, Grzywa R, Dyguda-Kazimierowicz E, Hamon Y, Legowska M, Skorenski M, Dallet-Choisy S, Marchand-Adam S, Kellenberger C, et al. Exploiting the S4-S5 specificity of human neutrophil proteinase 3 to improve the potency of peptidyl Di(chlorophenyl)-phosphonate Ester inhibitors: a kinetic and molecular modeling analysis. J Med Chem. 2018;61:1858–70.PubMedCrossRef
15.
Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MNG. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J Mol Biol. 1996;261:267–77.PubMedCrossRef
16.
Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and Cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010;62:726–59.PubMedPubMedCentralCrossRef
17.
Rao NV, Wehner NG, Marshall BC, Gray WR, Gray BH, Hoidal JR. Characterisation of proteinase 3 (PR-3), a neutrophil serine proteinase: structural and functional properties. J Biol Chem. 1991;266:9540–8.PubMed
18.
Brubaker MJ, Groutas WC, Hoidal JR, Rao NV. Human neutrophil proteinase 3: mapping of the substrate binding site using peptidyl Thiobenzyl esters. Biochem Biophys Res Commun. 1992;188:1318–24.PubMedCrossRef
19.
Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967;27:157–62.PubMedCrossRef
20.
Twigg MS, Brockbank S, Lowry P, FitzGerald SP, Taggart C, Weldon S. The role of serine proteases and Antiproteases in the cystic fibrosis lung. Mediat Inflamm. 2015;2015:10.CrossRef
21.
22.
23.
Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol. 2000;165:3366–74.PubMedCrossRef
24.
Loison F, Xu Y, Luo HR. Proteinase 3 and serpin B1: a novel pathway in the regulation of Caspase-3 activation, neutrophil spontaneous apoptosis, and inflammation. Inflamm Cell Signal. 2014;1:1–5.
25.
Zani ML, Nobar SM, Lacour SA, Lemoine S, Boudier C, Bieth JG, Moreau T. Kinetics of the inhibition of Neutriophil proteinases by recombinant Elafin and pre-elafin (Trappin-2) expressed in Pichia pastoris. Eur J Biochem. 2004;271:2370–8.PubMedCrossRef
26.
Yang L, Mei Y, Fang Q, Wang J, Yan Z, DSong Q, Lin Z, Ye G. Identification and characterization of serine protease inhibitors in a parasitic wasp, Pteromalus puparum. Sci Rep. 2017;7:1-13.
27.
Sinden NJ, Baker MJ, Smith DJ, Kreft J-U, Dafforn TR, Stockley RA. Alpha-1-antitrypsin variants and the proteinase/anti-proteinase imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015;308:12.CrossRef
28.
Jerke U, Perez Hernandez D, Beaudette P, Korkmaz B, Dittmar G, Kettritz R. Neutrophil Serine Proteases Exert Proteolytic Activity on Endothelial Cells. Kidney Int. 2015;88:764–75.PubMedCrossRef
29.
Korkmaz B, Lesner A, Guarino C, Wysocka M, Kellenberger C, Watier H, Specks U, Gauthier F, Jenne DE. Inhibitors and antibody fragments as potential anti-inflammatory therapeutics Targetting neutrophil proteinase 3 in human disease. Pharmacol Rev. 2016;68:603–30.PubMedCrossRef
30.
Guyot N, Wartelle J, Malleret L, Todorov AA, Devouassoux G, Pacheco Y, Jenne DE, Belaaouaj A. Unopposed Cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema. Am J Pathol. 2014;184:2197–210.PubMedCrossRef
31.
Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, Pham CT, van der Meer JW, Dinarello CA, van den Berg WB. Inflammatory Arthritis in Caspase 1 Gene-deficient Mice: Contribution of Proteinase 3 to Caspase 1-independent Production of Bioactive Interleukin-1beta. Arthritis Rheum. 2009;60:3651–62.PubMedPubMedCentralCrossRef
32.
Kessenbrock K, Frohlich L, Sixt M, Lammermann T, Pfister H, Bateman A, Belaaouaj A, Ring J, Ollert M, Fassler R, Jenne DE. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating anti-inflammatory Progranulin. J Clin Invest. 2008;118:2438–47.PubMedPubMedCentral
33.
Gudmann NS, Manon-Jensen T, Sand JMB, Diefenbach C, Sun S, Danielsen A, Karsdal MA, Leeming DJ. Lung tissue destruction by proteinase 3 and Cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2018;503(3):1284-90.PubMedCrossRef
34.
Newby PR, Carter RI, Stockley RA. Aα-Val541 a Novel Biomarker of Proteinase 3 Activity. Am J Respir Crit Care Med. 2017;195:A5247.
35.
Newby PR, Stockley RA. Neutrophil elastase and proteinase 3 activity in PiSZ Alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2018;197:A4763.
36.
Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Too little, too late or too much, too soon? Am J Respir Cell Mol Biol. 2013;48:531–9.PubMedCrossRef
37.
Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in α1-antitrypsin deficiency. CHEST. 2000;117:303S.PubMedCrossRef
38.
Stockley RA. Neutrophils and protease/Antiprotease imbalance. Am J Respir Crit Care Med. 1999;160:S49–52.PubMedCrossRef
39.
Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol. 1999;65:14.CrossRef
40.
Maximova K, Venken T, Reuter N, Trylska J. D-peptides as inhibitors of PR3-membrane interactions. Biomembranes. 1860;2018:458–66.
41.
Korkmaz B, Poutrain P, Hazouard E, de Monte M, Attucci S, Gauthier FL. Competition between elastase and related proteases from human neutrophil for binding to α1-protease inhibitor. Am J Respir Cell Mol Biol. 2005;32:553–9.PubMedCrossRef
42.
Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with Alpha-1 anti-trypsin deficiency and COPD. Eur Respir J. 2013;41:1042–50.PubMedCrossRef
43.
Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human Polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest. 1988;82:1963–73.PubMedPubMedCentralCrossRef
44.
Borel F, Sun H, Zieger M, Cox A, Cardozo B, Li W, Oliveira G, Davis A, Gruntman A, Flotte TR, et al. Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. Proc Natl Acad Sci U S A. 2018;115(11):2788-93.CrossRef
45.
Lombard C, Bouchu D, Wallach J, Saulnier J. Proteinase 3 hydrolysis of peptides derived from human elastin exon 24. Amino Acids. 2005;28:403–8.PubMedCrossRef
46.
Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 2012;40:766–82.PubMedCrossRef
47.
Sand JMB, Knox AJ, Lange P, Sun S, Kristensen JH, Leeming DJ, Karsdal MA, Bolton CE, Johnson SR. Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res. 2015;16:69.PubMedPubMedCentralCrossRef
48.
Ramaha A, Patston PA. Release and degradation of angiotensin 1 and angiotensin 2 from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys. 2002;397:77–83.PubMedCrossRef
49.
Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I, Canteloup S, Lenoir G, Descamps-Latscha B, Nadel JA. Proteinase 3, a potent Secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol. 1999;20:729–36.PubMedCrossRef
50.
Janciauskiene S, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of Alpha-1-antitrypsin and its role in health and disease. Respir Med. 2011;105:1129–39.PubMedCrossRef
51.
Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood J. 2001;97:3951–9.CrossRef
52.
Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev. 2009;60:57–64.PubMedCrossRef
53.
Popa C, Netea MG, van Riel PLCM, van der Meer JWM, Stalenhoef AFH. The role of TNF-a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48:751–62.PubMedCrossRef
54.
Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, Leimer AH, Cheronis J. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human Monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A. 1999;96:6261–6.PubMedPubMedCentralCrossRef
55.
Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine. 2014;69:136-45.PubMedCrossRef
56.
Schreiber A, Pham CT, Hu Y, Schneider W, Luft FC, Kettritz R. Neutrophil serine proteases promote IL-1beta generation and injury in necrotizing crescentic glomerulonephritis. J Am Soc Nephrol. 2012;23:470–82.PubMedPubMedCentralCrossRef
57.
Sugawara A, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A, Hanzawa K, Kumagai K, Okamura H, Takada H. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human Oral epithelial cells. J Immunol. 2001;167:6568–75.PubMedCrossRef
58.
59.
Hurst SM, Wilkinson TS, McLoughline RM, Jones S, Horiuchi S, Yamamoto N, Rose-john S, Fuller GM, Topley N, Jones SA. IL-6 and its soluble receptor Ochestrate a Temportal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705–14.CrossRefPubMed
60.
McLoughlin RM, Hurst SM, Nowell MA, Harris DA, Horiuchi S, Morgan LW, Wilkinson TS, Yamamoto N, Topley N, Jones SA. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol. 2004;172:5676–83.PubMedCrossRef
61.
Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in Interleukin-8 and tumour necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:512–21.CrossRef
62.
Rani L, Minz RW, Sharma A, Anand S, Gupta D, Panda NK, Sakhuja VK. Predominance of PR3 specific immune response and skewed Th17 vs. T-regulatory Miliew in active Granfulomatosis with Polyangiitis. Cytokine. 2015;71:7.CrossRef
63.
Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFα. Immunity. 2005;22:131–42.PubMed
64.
Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, Sfriso P. IL-32, a novel Proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:894–901.PubMedCrossRef
65.
66.
Nemeth T, Mocsai A. Feedback amplification of neutrophil function. Cell. 2016;37:412–24.
67.
Robache-Gallea S, Morand V, Bruneau JM, Schoot B, Tagat E, Realo E, Chouaib S, Roman-Roman S. In vitro processing of human tumour necrosis factor-alpha. J Biol Chem. 1995;270:23688–92.PubMedCrossRef
68.
Kessenbrock K, Dau T, Jenne DE. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. J Mol Med. 2011;89:23–8.PubMedCrossRef
69.
Ungers MJ, Sinden NJ, Stockley RA. Progranulin is a substrate for neutrophil-elastase and Proteinase-3 in the airway and its concentration correlates with mediators of airway inflammation in COPD. Am J Physiol Lung Cell Mol Physiol. 2014;306:L80–7.CrossRef
70.
Couto MA, Harwig SSL, Cullor JS, Hughes JP, Lehrer RI. eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. Infect Immun. 1992;60:5042–7.PubMedPubMedCentral
71.
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnivk AD, Rollinson S, et al. Mutations in Progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–9.PubMedCrossRef
72.
Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdujument-Bromage H, Tempst P, Wright CD, Ding A. Conversion of Proepithelin to Epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 2002;111:867–78.PubMedCrossRef
73.
van der Berg CW, Tambourgi DV, Clark HW, Hoong SJ, Spiller OB, McGreal EP. Mechanism of neutrophil dysfunction: neutrophil serine proteases cleave and inactivate the C5a receptor. J Immunol. 2014;192:1787–95.CrossRef
74.
Marc MM, Korosec P, Kosnik M, Kern I, Flezar M, Suskovic S, Sorli J. Complement factors C3a, C4a, and C5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol. 2004;31:216–9.PubMedCrossRef
75.
Zhang Y, Jiang Y, Sun C, Wang Q, Yang Z, Pan X, Zhu M, Xiao W. The human cathelicidin LL-37 enhances airway mucus production in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2014;443:103–9.PubMedCrossRef
76.
Campanelli D, Detmers PA, Nathan CF, Gabay JE. Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest. 1990;85:904–15.PubMedPubMedCentralCrossRef
77.
Dasaraju PV, Liu C. Infections of the respiratory system. In: Medical Microbiology. 4th ed. Baron S, editor. Texas: University of Texas Medical Branch at Galveston; 1996.
78.
Kuroda K, Okumura K, Isogai H, Isogai E. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anti-Cancer drugs. Front Oncol. 2015;5:10.CrossRef
79.
Jiang Y-Y, Xiao W, Zhu M-X, Yang Z-H, Pan X-J, Zhang Y, Sun C-C, Xing Y. The effect of human antibacterial peptide LL-37 in the pathogenesis of chronic obstructive pulmonary disease. Respir Med. 2012;106:1680–9.PubMedCrossRef
80.
Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, Brinkmann V, Jungblut PR, Sycglinsky A. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009;5:e1000639.PubMedPubMedCentralCrossRef
81.
Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, Grone H-J, Brinkmann V, Jenne DE. Netting Neutrophils in Autoimmune Small-Vessel Vasculitis. Nat Med. 2009;15:623–5.PubMedPubMedCentralCrossRef
82.
Delgado-Rizo V, Martinez-Guzman MA, Iniguez-Gutierrez L, Garcia-Orozco A, Alvarado-Navarro A, Fafutis-Morris M. Neutrophil extracellular traps and its implications in inflammation: an overview. Front Immunol. 2017;2017:1–20.
83.
Beiter K, Wartha F, Albiger B, Normark S, Zychlinsky A, Henriques-Normark B. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol. 2006;16:401–7.PubMedCrossRef
84.
Hong W, Juneau RA, Pang B, Swords WE. Survival of bacterial biofilms within neutrophil extracellular traps promotes Nontypeable Haemophilus influenzae persistence in the Chinchilla model for otitis media. J Innate Immun. 2009;1:215–24.PubMedCrossRefPubMedCentral
85.
Benarafa C, Priebe GP, Remold-O'Donnell E. The neutrophil serine protease inhibitor SerpinB1 preserves lung Defence functions in Pseudomonas aeruginosa infection. J Exp Med. 2007;204:1901–9.PubMedPubMedCentralCrossRef
86.
Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory leukocyte protease inhibitor with Proteinase-3. Am J Respir Cell Mol Biol. 1993;8:612-6.PubMedCrossRef
87.
Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737–44.PubMedCrossRef
88.
Kolonin AG, Sergeeva A, Staquicini DI, Smith TL, Tarleton CA, Molldrem JJ, Sidman RL, Marchio S, Pasqualini R, Arap W. Interaction between tumour cell surface receptor RAGE and proteinase 3 mediates prostate Cancer Matastasis to bone. Cancer Res. 2017;77:3144–50.PubMedPubMedCentralCrossRef
89.
Sukkar MB, Ullah MA, Gan WJ, Wark PAB, Chung KF, Hughes JM, Armour CL, Phipps S. RAGE: a new frontier in chronic airways disease. Br J Pharmacol. 2012;167:1161–76.PubMedPubMedCentralCrossRef
90.
Yonchuk JG, Silverman EK, Bowler RP, Agusti A, Lomas DA, Miller BE, Tal-Singer R, Mayer RJ. Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE Axis in the lung. Am J Respir Crit Care Med. 2015;192:785–92.PubMedCrossRef
91.
92.
93.
Toonen EJ, Mirea AM, Tack CJ, Stienstra R, Ballak DB, van Diepen JA, Hijmans A, Chavakis T, Dokter WH, Pham CT, et al. Activation of proteinase 3 contributes to non-alcoholic fatty liver disease (NAFLD) and insulin resistance. Mol Med. 2016;22:202–14.PubMedCentralCrossRef
94.
95.
Matsumoto T, Kaneko T, Seto M, Wada H, Kobayashi T, Nakatani K, Tonomura H, Tono Y, Ohyabu M, Nobori T, et al. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost. 2008;14:186-92.CrossRef
96.
Armstrong L, Godinho SIH, Uppington KM, Whittington HA, Millar AB. Tumour necrosis factor-α processing in interstitial lung disease: a potential role for exogenous Proteinase-3. Clin Exp Immunol. 2009;156:336–43.PubMedPubMedCentralCrossRef
97.
McGreal EP, Davies PL, Powell W, Rose-John S, Spiller OB, Doull I, Jones SA, Kotecha S. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochim Biophys Acta. 2010;1802:649–58.PubMedCrossRef
98.
Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis. 2006;65:4.CrossRef
99.
Zhao Y-P, Tian Q-Y, Liu C-J. Progranulin deficiency exaggerates, whereas Progranulin-derived Atsttrin attenuates, severity of dermatitis in mice. FEBS Lett. 2013;587:6.
100.
Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, et al. The growth factor Progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:7.
101.
Guo Z, Li Q, Han Y, Liang Y, Xu Z, Ren T. Prevention of LPS-induced acute lung injury in mice by Progranulin. Mediat Inflamm. 2012;2012:10.CrossRef
102.
Goedert M, Spillantini MG. Frontotemporal lobar degeneration through loss of Progranulin function. Brain Res Rev. 2006;129:2808–10.
103.
Bossu P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, Scarpini E, Spalletta G, Caltagirone C, Padovani A, Borroni B. Loss of function mutations in the Progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation. 2011;8:65–9.PubMedPubMedCentralCrossRef
104.
Cruts M, van Broeckhoven C. Loss of Progranulin function in frontotemporal lobar degeneration. Trends Genet. 2008;24:186–94.PubMedCrossRef
105.
106.
Kuckleburg CJ, Tilkens SM, Santoso S, Newman PJ. Proteinase 3 contributes to Transendothelial migration of NB1-positive neutrophils. J Immunol. 2012;188:2419–26.PubMedCrossRef
107.
Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key regulators of cell Signalling during inflammation. J Intern Med. 2005;257:319–28.PubMedCrossRef
108.
Saragih H, Zilian E, Jaimes Y, Paine A, Figueiredo C, Eiz-Vesper B, Blascysk R, Larmann J, Theilmeier G, Burg-Roderfeld M, et al. PECAM-1-dependent Heme Oxygenase-1 regulation via an Nrf2-mediated pathway in endothelial cells. Thromb Haemost. 2014;111:1077–88.PubMedCrossRef
109.
Lutz PG, Houzel-Charavel A, Moog-Lutz C, Cayre YE. Myeloblastin is an Myb target gene: mechanisms of Regulationin myeloid leukemia cells growth-arrested by retinoic acid. Blood Journal. 2001;97:2449–56.CrossRef
110.
Lutz PG, Moog-Lutz C, Coumau-Gatbois E, Kobari L, di Gioia Y, Cayre YE. Myeloblastin is a granulocyte Colony-stimulating factor-responsive gene conferring factor-independent growth to Haematopoietic cells. Proc Natl Acad Sci U S A. 2000;97:1601–6.PubMedPubMedCentralCrossRef
111.
Bories D, Raynal M-C, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, Myeloblastin, causes growth arrest and differentiation of Promyelocytic leukemia cells. Cell. 1989;59:959–68.PubMedCrossRef
112.
Martin KR, Kantarl-Mimoun C, Yin M, Perderzoll-Ribell M, Angelot-Delettre F, Cerol A, Grauffel C, Benhamou M, Reuter N, Saas P, et al. Proteinase 3 is a phosphatidylserine-binding protein that affects the production and function of microvesicles. J Biol Chem. 2016;291:10476–89.PubMedPubMedCentralCrossRef
113.
Cerezo LA, Kuklova M, Hulejova H, Vernerova Z, Kasprikova N, Veigl D, Pavelka K, Vencovsky J, Senolt L. Progranulin is associate with disease activity in patients with Rheumatiod arthritis. Mediat Inflamm. 2015;2015:6.
114.
115.
Hozumi H, Enomoto N, Oyama Y, Kono M, Fujisawa T, Inui N, Nakamura Y, Suda T. Clinical implication of Proteinase-3-Antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias. Lung. 2016;194:235–42.PubMedCrossRef
116.
Seo P, Stone JH. The Antineutrophilic cytoplasmic antibody-associated Vasulitides. Am J Med. 2004;117:39–50.PubMedCrossRef
117.
Falk RJ, Jennette JC. Wegener's granulomatosis systemic Vasculitis, and Antineutrophil cytoplasmic autoantibodies. Annu Rev Med. 1991;42:459–69.PubMedCrossRef
118.
119.
Bonarius HPJ, Brandsma CA, Kerstjens HAM, Koerts JA, Kerkhof M, Nizankowska-Mogilnicka E, Roozendaal C, Postma DS, Timens W. Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking history. Thorax. 2011;66:101–7.PubMedCrossRef
120.
Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, Hagen EC, Jayne D, Jennette JC, Paspaliaris B, et al. International consensus statement on testing and reporting of Antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507–13.PubMedCrossRef
121.
Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, McEvoy R, Pusey C, Pollock W, Trevisin M, et al. Addendum to the international consensus statement on testing and reporting of Antineutrophil cytoplasmic antibodies. Am J Clin Pathol. 2003;120:312–8.PubMedCrossRef
122.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL, Fitzgerald J, Checchia PA, Meyer K, et al. A multibiomarker-based model for estimating the risk of septic acute kidney injury. Crit Care Med. 2015;43:1646–53.PubMedPubMedCentralCrossRef
123.
Ng LL, Khan SQ, Narayan H, Quinn P, Squire IB, Davies JE. Proteinase 3 and prognosis of patients with acute myocardial infarction. Clin Sci. 2011;120:231–8.CrossRef
124.
Carter RI, Ungers MJ, Mumford RA, Stockley RA. Aa-Val360: a marker of Neurophil elastase and COPD disease activity. Eur Respir J. 2013;41(1):31-8.PubMedCrossRef
Metadata
Title
Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases
Authors
Helena Crisford
Elizabeth Sapey
Robert A. Stockley
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2018
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-018-0883-z

Other articles of this Issue 1/2018

Respiratory Research 1/2018 Go to the issue

Research

miR-34a is involved in CSE-induced apoptosis of human pulmonary microvascular endothelial cells by targeting Notch-1 receptor protein

Research

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

Research

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis

Research

Soluble epoxide hydrolase derived lipid mediators are elevated in bronchoalveolar lavage fluid from patients with sarcoidosis: a cross-sectional study

Research

SOX30 specially prevents Wnt-signaling to suppress metastasis and improve prognosis of lung adenocarcinoma patients

Research

Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits